Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1808 results
May 2016
-
Media ReleaseNovartis Foundation and partners launch innovative hypertension program in VietnamHo Chi Minh City Communities for Healthy Hearts Program is the second innovative healthcare model for hypertension pioneered by the Novartis Foundation Screening and treatment shifts to the…
-
Electrical brainstorms traced to genetic mutations
Researchers from Seattle Children’s and Novartis shed light on developmental brain disorders that lead to intractable epilepsy.
-
Media ReleaseMajor study published in NEJM confirms Novartis' Ultibro® Breezhaler® superiority over Seretide® in preventing COPD exacerbationsFLAME study showed consistent superiority of Ultibro® Breezhaler® over Seretide® across exacerbation outcomes, lung function and health-related quality of life in COPD patients Ultibro…
-
Eye disease tracked to a glitch in starburst cells
A cellular computing error wreaks havoc on vision.
-
In The NewsNovartis Access perspectives: Fighting Africa's future epidemicsAn editorial for the World Economic Forum by Harald Nusser, Head Novartis Access & Malaria Initiative
April 2016
-
Media ReleaseNovartis drug Afinitor® recommended by CHMP for European Union approval to treat select GI and lung neuroendocrine tumorsIf approved, Afinitor would be first treatment in EU indicated for advanced progressive, nonfunctional lung NET and first oral therapy for this type of GI NET Advanced, progressive, nonfunctional…
-
Collaborating to unlock secrets of the microbiome
Novartis and Broad Institute researchers explore how gut bacteria contribute to health and disease, beginning with type 1 diabetes.
-
Media ReleaseNovartis receives three FDA Breakthrough Therapy Designations for Ilaris to treat rare types of Periodic Fever SyndromesSubject to approvals, Ilaris® will likely be first FDA-approved treatment for TRAPS and HIDS/MKD, and an important alternative treatment for patients with FMF Designations support potential…
-
Patient advocacy at work: one man’s contributions to the COPD community
Read how one caregiver established an association to provide resources for both COPD patients and caregivers.
-
Talking to: Bruno Strigini on why we're entering a transformative time in cancer care
Accelerating Research to Get Answers Faster
-
Media ReleaseNovartis delivered solid Q1 despite Gleevec loss of exclusivity; investing behind new launches for long-term growthNet sales up 1% (cc[1]), as Growth Products offset Gleevec impact Growth Products[2] grew 24% (USD) to USD 3.9 billion, or 34% of Group net sales Cosentyx (USD 176 million) continues to grow…
-
Media ReleaseNovartis erzielt im ersten Quartal trotz Verlust der Exklusivrechte an Gleevec solide Ergebnisse und investiert in Neueinführungen zugunsten langfristigen WachstumsDer Nettoumsatz steigt um 1% (kWk[1]), da die Wachstumsprodukte die Einbussen bei Gleevec kompensieren Die Wachstumsprodukte[2] steigern den Umsatz um 24% (USD) auf USD 3,9 Milliarden bzw. 34%…
Pagination
- ‹ Previous page
- 1
- …
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- …
- 151
- › Next page